Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Corbus Pharmaceuticals Holdings, Inc. is not a good value stock. Corbus Pharmaceuticals Holdings, Inc. is not a good growth stock. Corbus Pharmaceuticals Holdings, Inc. is a mediocre stock to choose.

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focu...

News

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Buy" by Analysts

Ticker Report Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given a consensus rating of "Buy" by the seven research firms that are presently covering the stock...\n more…

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

Globe Newswire NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...\n more…

Corbus Pharmaceuticals Holdings, Inc. Expected to Earn Q3 2024 Earnings of ($1.03) Per Share (NASDAQ:CRBP)

Zolmax Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Lifesci Capital issued their Q3 2024 EPS estimates for shares of Corbus Pharmaceuticals in a research note issued on Wednesday...\n more…

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet

Zacks Investment Research Corbus Pharmaceuticals (CRBP) closed the last trading session at $59.70, gaining 2.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set...\n more…

Lifesci Capital Comments on Corbus Pharmaceuticals Holdings, Inc.'s Q3 2024 Earnings (NASDAQ:CRBP)

Ticker Report Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at Lifesci Capital issued their Q3 2024 earnings estimates for shares of Corbus Pharmaceuticals in a research note...\n more…

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Globe Newswire NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), today announced the appointment of Winston Kung to its Board of...\n more…